Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer

Biologics: Targets and Therapy

Volumn 2, Issue 3, 2008, Pages 555-561

  Lasalvia Prisco, Eduardo ^a,d   Garcia Giralt, Emilio ^b   Vázquez, Jesús ^b,d   Aghazarian, Marta ^d   Lasalvia Galante, Eduardo ^c,d   Larrañaga, Joshemaria ^c,d   Spera, Gonzalo ^c  

^a Interdoctors Medical Procedures   (United States)

^b Centre De Cancerologie Hartmann   (France)

^c Interdoctors   (Uruguay)

^d National Institute of Oncology   (Uruguay)

Author keywords

Cancer therapy; Cancer vaccine; Immunomodulatory cancer treatment; Immunotherapy adjuvants; Lung cancer chemoimmunotherapy; Lung cancer chemotherapy

Indexed keywords

EID: 83455236071     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s2685     Document Type: Article

References (38)

1. Altman DG, Schulz KF, Moher D, et al. 2001. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med, 134:663-94.
2. [ALA] American Lung Association. 2005. Epidemiology and statistical unit. Research and program services. Trends in lung cancer morbidity and mortality.
3. Berd D, Mastrangelo MJ, Engstrom PF, et al. 1982. Augmentation of the human immune response by cyclophosphamide. Can Res, 42:4862-6.
4. Chretien PB, Lipson SD, Makuch RW, et al. 1979. Effects of thymosin in vitro in cancer patients and correlation with clinical course after thymosin immunotherapy. Ann N Y Acad Sci, 332:135-47.
5. Cochran AJ, Huang RR, Lee J, et al. 2006. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol, 6:659-70.
6. Disis ML, Bernhard H, Shiota FM, et al. 1996. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptidebased vaccines. Blood, 88:202-20.
7. Dranoff G. 2002. GM-CSF-based cancer vaccines. Immunol Rev, 188:147-54.
8. Fauve RM, Fontan E, Hevin MB, et al. 1987. Remote effects of inflammation on non-specific immunity. Immunol Lett, 16(3-4):199-203.
9. Fauve RM, Hevin MB. 1977. Inflammation et Résistance Antitumore. Ann Immunol (Inst Pasteur), 128C:923-8.
10. Feng H, Zeng Y, Graner MW, et al. 2002. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood (Immunobiology), 100:4108-15.
11. Fontan E, Fauve RM, Hevin MB, et al. 1983. Immunostimulatory mouse granuloma protein. Proc Nat Acad Sci USA, 80:6395-8.
12. Fontan E, Saklani-Jusforgues H, Fauve RM. 1992. Immunostimulatory human urinary protein. Proc Natl Acad Sci USA, 89:4358-62.
13. Garcia-Giralt E, Lasalvia-Prisco E, Cucchi S, et al. 2006. Ovarian cancer: autologous immunotherapy optimized by remote adjuvancy of a silicate- induced granuloma [abstract]. Am Soc Clin Oncol (ASCO), 42nd Annual Meeting, 12515.
14. Garcia-Giralt E, Lasalvia-Prisco E, Cucchi S, et al. 2007. Breast cancer: draining lymph node of vaccination site targeted by adjuvant GM-CSF in an autologous vaccine [abstract]. Am Soc Clin Oncol (ASCO), 43rd Annual Meeting, 13506.
15. Georgoulias V, Ardavanis A, Agelidou A, et al. 2004. Doxetacel versus doxetacel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol, 22:2602-9.
16. Ghiringhelli F, Larmonier N, Schmitt E, et al. 2004. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol, 34:336-44.
17. Hadźiev S, Mandulova P, Kavaklieva-Dimitrova J, et al. 1982. BCG immunotherapy of lung cancer in a district oncology dispensary. I. Study of 860 patients with histologic diagnosis. Neoplasma, 29:93-110.
18. Issell BF, Valdivieso M, Hersh EM, et al. 1978. Combination chemoimmunotherapy for extensive non-oat cell lung cancer. Cancer Treat Rep, 62:1059-63.
19. Lasalvia-Prisco E, Cucchi S, Vázquez J, et al. 2003. Antitumor effect of a vaccination procedure with an autologous hemoderivative. Cancer Biol Ther, 2:155-60.
20. Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S, et al. 2006a. Advanced colon cancer: antiprogressive immunotherapy using an autologous hemoderivative. Med Oncol, 23:91-104.
21. Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S, et al. 2006b. Advanced breast cancer: Antiprogressive immunotherapy using a thermostable autologous hemoderivative. Breast Cancer Res Treat, 100:149-60.
22. Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S, et al. 2007a. Advanced ovarian cancer: Vaccination site draining lymph node as target of immunomodulative adjuvants in autologous cancer vaccine. Biologics Targ Ther, 1:173-81.
23. Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S, et al. 2007b. Conditioning of vaccine sentinel lymph node as adjuvant of autologous hemoderivative breast cancer vaccine [abstract]. 14th European Cancer Conference. Barcelona, 804.
24. Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S, et al. 2007c. Prostate cancer: vaccine Sentinel Immunized Node (SIN) target for adjuvant locoregional chemotherapy in autologous vaccine [abstract]. Am Soc Clin Oncol (ASCO), 43rd Annual Meeting, 13500.
25. Lynch TJ, Bell DW, Sordella R, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med, 350:2129-39.
26. Melcher A, Gough M, Todryk S, et al. 1999. Apoptosis or necrosis for tumor immunotherapy: What is in a name? J Mol Med, 77:824-33.
27. Melcher A, Todryk S, Hardwick N, et al. 1998. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression, Nat Med, 4:581-7.
28. Moher D, Schulz KF, Altman DG. 2001. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet, 357:1191-4.
29. [NCI] National Cancer Institute, US. 2006: Common terminology criteria or adverse events V3.0 (CTCAE).
30. Oken MM, Creech RH, Tormey DC, et al. 1982. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5:649-55.
31. Pinedo HM, Gruijl TD, van der Wall E, et al. 2000. Biological concepts of prolonged neoadjuvant treatment plus GM-CSF in locally advanced tumors. Oncologist, 5:497-500.
32. Raez LE, Fein S, Podack ER. 2005. Lung cancer immunotherapy. Clin Med Res, 3:221-8.
33. Rini B, Weinberg V, Fong L, et al. 2005. Clinical and immunologic characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with GM-CSF [abstract]. Prostate Cancer Symposium, 261.
34. Socinski MA, Morris DE, Masters GA, et al. 2003. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest, 123:226S-43S.
35. Taylor JM, Braun TM, Li Z. 2006. Comparing an experimental agent to a standard agent: merits of a one-arm or randomized two-arm Phase II design. Clin Trials, 3:335-48.
36. Therasse P, Arbuck SG, Einsenhauer EA, et al. 2000. New guideline to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat Cancer Inst, 92:205-16.
37. Tiligada E. 2006. Chemotherapy: induction of stress responses. Endocr Relat Cancer, 13(Suppl 1):S115-124.
38. [WMA] World Medical Association. 1997. Declaration of Helsinki: Recommendations guiding medical doctors in biomedical research involving human subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964 and as revised in Tokyo, 1975, in Venice, 1983, in Hong Kong, 1989. Version with changes in 1997.